Osteocalcin and osteoprotegerin levels and their relationship with adipokines and proinflammatory cytokines in children with nonalcoholic fatty liver disease

Ethnopharmacological Relevance. The Hugan Qingzhi tablet (HQT) is a traditional Chinese medicine used for treating NAFLD (nonalcoholic fatty liver disease). The present study evaluated the anti-inflammatory effects of HQT in rats with NAFLD.Materials and Methods. HQT was administered daily to the NAFLD experimental groups. Biochemical markers, histopathological data, and oxidative stress/antioxidant biomarkers were determined. Proinflammatory cytokines interleukin-1β(IL-1β), tumor necrosis factorα(TNF-α), and interleukin-6 (IL-6) were detected by enzyme-linked immunoassay. Expressions of silent information regulator 1 (SIRT1) and acetylated-nuclear-factor kappaB-p65 (Ac-NF-κB-p65) were performed by western blotting.Results. At high and moderate doses, HQT was highly effective in decreasing serum alanine aminotransferase (P<0.01), aspartate aminotransferase (P<0.01), hepatic total cholesterol (P<0.01), triglycerides (P<0.01), and free fatty acid levels (P<0.01). Moreover, high and moderate doses of HQT reduced hepatic levels of the proinflammatory cytokines TNF-α(P<0.01), IL-1β(P<0.01), and IL-6 (P<0.01), enhanced SIRT1 expression, and depressed Ac-NF-κB-p65 expression at protein level.Conclusions. In our NAFLD rat model, HQT exerted substantial anti-inflammatory and antioxidant activities, possibly involving the regulation of SIRT1 and Ac-NF-κB-p65 expression.

Download Full-text

Factors governing development of nonalcoholic fatty liver disease and insulin resistance in obesity

Biomeditsinskaya Khimiya ◽

10.18097/pbmc20186405444 ◽

2018 ◽

Vol 64 (5) ◽

pp. 444-450 ◽

Cited By ~ 1

Author(s):

M.A. Vulf ◽

E.V. Kirienkova ◽

D.A. Skuratovskaia ◽

E.V. Levada ◽

L.V. Volkova ◽

...

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Nonalcoholic Fatty Liver Disease ◽

Proinflammatory Cytokines ◽

Fatty Liver Disease ◽

Comparison Group ◽

Obese Patients ◽

Hsp70 Gene ◽

Nonalcoholic Fatty Liver

The factors promoting development of non-alcoholic fatty liver disease in patients with obesity and different state of carbohydrate metabolism have been studied. 43 patients were examined; these included 26 patients with abdominal obesity (BMI=52.9±7.9 kg/m2). The control group consisted of 17 conditionally healthy donors without obesity (BMI=18.9-24.9 kg/m2), seven of them formed a comparison group that was included to compare the results of study on the levels of tissue-specific expression of HSP70 mRNA. The study of mRNA expression was performed by real-time PCR. The concentration of IL-6 and TNF-a was measured in blood serum by the ELISA method. In patients with obesity with diabetes mellitus type 2 (DM2), a significant increase in the serum level of proinflammatory cytokines was found in comparison with the group of patients without DM2 and control. The results of histological examination of liver biopsy specimens in obese patients revealed the most pronounced changes in the group of DM2 patients. Regardless of the stage of nonalcoholic fatty liver disease in obese DM2 patients, an increase in the area of fatty inclusions (relative to the group without type 2 diabetes) was recorded. The study of the HSP70 gene expression in peripheral blood mononuclear cells allowed its significant increase relative to the comparison group. The relationship between the level of expression of the HSP70 gene in metabolically active tissues (visceral, subcutaneous adipose tissue and liver) established in all obese patients with the serum content of proinflammatory cytokines (IL-6 and TNF-a) may indicate suppression of HSP70 expression in these tissues, background of systemic and local inflammation in obesity.

Download Full-text

Proinflammatory cytokines and endotoxemia level change in patients with type 2 diabetes and nonalcoholic fatty liver disease after hepatoprotective and probiotic therapy usage

Endocrine Abstracts ◽

10.1530/endoabs.56.gp93 ◽

2018 ◽

Author(s):

Kateryna Kondratiuk ◽

Mykola Lysianyj ◽

Kondratiuk Valentyna ◽

Galyna Myhalchyshyn

Keyword(s):

Type 2 Diabetes ◽

Liver Disease ◽

Fatty Liver ◽

Nonalcoholic Fatty Liver Disease ◽

Proinflammatory Cytokines ◽

Fatty Liver Disease ◽

Nonalcoholic Fatty Liver ◽

Level Change

Download Full-text

Antiresistin RNA Oligonucleotide Ameliorates Diet-Induced Nonalcoholic Fatty Liver Disease in Mice through Attenuating Proinflammatory Cytokines

BioMed Research International ◽

10.1155/2015/414860 ◽

2015 ◽

Vol 2015 ◽

pp. 1-13 ◽

Cited By ~ 3

Author(s):

Yi Tan ◽

Xing Liang Jin ◽

Weiguo Lao ◽

Jane Kim ◽

Linda Xiao ◽

...

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Nonalcoholic Fatty Liver Disease ◽

Proinflammatory Cytokines ◽

Fatty Liver Disease ◽

Phosphoenolpyruvate Carboxykinase ◽

Regulatory Element ◽

Elevated Serum ◽

Tolerance Test ◽

Nonalcoholic Fatty Liver

The aim of this study was to determine whether inhibition of resistin by a synthetic antiresistin RNA (oligonucleotide) oligo ameliorates metabolic and histological abnormalities in nonalcoholic fatty liver disease (NAFLD) induced by high-fat diet (HFD) in mice. The antiresistin RNA oligo and a scrambled control oligo (25 mg/kg of body weight) were i.p. injected to HFD mice. Serum metabolic parameters and hepatic enzymes were measured after 4-week treatment. The treatment significantly reduced epididymal fat and attenuated the elevated serum resistin, cholesterol, triglycerides, glucose, and insulin with an improved glucose tolerance test. Antiresistin RNA oligo also normalized serum AST and ALT levels with improved pathohistology of NAFLD. Immunoblotting and qRT-PCR revealed that decreased protein and mRNA expression of resistin in fat and liver tissues of the treated mice were associated with reduction of adipose TNF-αand IL-6 expression and secretion into circulation. mRNA and protein expression of hepatic phosphoenolpyruvate carboxykinase (PEPCK) and sterol regulatory element-binding protein-1c (SREBP-1c) were also significantly decreased in the treated mice. Our results suggest that resistin may exacerbate NAFLD in metabolic syndrome through upregulating inflammatory cytokines and hepatic PEPCK and SREBP-1c. Antiresistin RNA oligo ameliorated metabolic abnormalities and histopathology of NAFLD through attenuating proinflammatory cytokines.

Download Full-text